

"Naloxone Education and Simulation"

December 14, 2021, 12:00 to 1:00 PM

Presenter Bio

Roisin Sabol, BSPS, PharmD Candidate (Speaker)

Pharmacy Intern
Western Psychiatric Hospital
Pittsburgh, PA

Roisin Sabol is a Pittsburgh native. She completed her undergraduate training at the University of Pittsburgh and started to explore her interest in psychiatry during that time through a research position in a psychiatric genetics laboratory. Soon into her undergraduate career, she realized her love of pharmacy and the opportunity to educate patients on both medications and disease states. She is now a PharmD Candidate at the University of Pittsburgh School of Pharmacy. After earning her PharmD in April 2022, she intends to complete a postgraduate pharmacy residency training program to enhance her clinical skills. Her ultimate goal is to become a Board-Certified Psychiatric Pharmacist.

Roisin has been an intern at Western Psychiatric Hospital pharmacy and Forbes Pharmacy since April 2019. This experience has furthered her passion for treating patients with mental illness. She has gained a more thorough understanding of the tremendous role that the entire patient care team plays in helping patients manage their illnesses. In particular, she is interested in treating patients with substance use disorders. With this passion comes her desire to educate community members and patients alike on harm-reduction tools such as naloxone. I have conducted numerous Naloxone Education and Simulation sessions through the University of Pittsburgh School of Pharmacy and Western Psychiatric Hospital. I am thrilled to present this session to CCBH and other UPMC staff members.

Tanya J. Fabian, PharmD, PhD (Faculty)

Associate Professor, Pharmacy, Therapeutics, and Psychiatry
University of Pittsburgh
Director of Pharmacy Research and Pharmacy Services
Residency Program Director for the PGY2 Psychiatric Pharmacy Residency Program
UPMC Western Psychiatric Hospital
Pittsburgh, PA

Tanya J. Fabian is Associate Professor of Pharmacy and Therapeutics and Psychiatry at the University of Pittsburgh. She received her PharmD degree from the University of Pittsburgh in 1998. A graduate of the Clinical Pharmaceutical Scientists Training Program, Dr. Fabian received her Doctor of Philosophy degree in Pharmaceutical Sciences in 2003. She also completed an NIH post-doctoral research fellowship in clinical geriatric psychiatry under the mentorship of Drs. Patricia D. Kroboth and Dr. Bruce G. Pollock.

Since 2006, Dr. Fabian has served as Director of Pharmacy Research and Pharmacy Services at Western Psychiatric Hospital and Residency Program Director for the PGY2 Psychiatric Pharmacy Residency Program. She became a Board-Certified Psychiatric Pharmacy Specialist in 2008.

Target Audience: All providers, family members, interested individuals.

Name and Narrative Description of your Presentation

"Naloxone Education and Simulation" (Introductory)

The Naloxone Education and Simulation session will provide education on an essential life-saving medication, naloxone. This program covers recent data, statistics, and trends related to the ongoing opioid epidemic and relates national data to state- and county-level data. The session also includes an overview of what naloxone is and when it should be used. We discuss safety information related to naloxone administration. Finally, we will experience a simulation of what it looks like when someone suffers an opioid-related overdose and understand how to administer naloxone in this situation.

Three (3) learning objectives

By the completion of this session, participants should be able to:

1. Explain recent trends related to the opioid epidemic.
2. Recognize the uses of naloxone, and the symptoms of when to administer it.
3. Describe and demonstrate the steps to administering naloxone.

Three (3) current (within the past 10 years) peer-reviewed publications that support the evidencebase for the content of your presentation

1. Chisholm-Burns, MA. (2019). The opioid crisis: origins, trends, policies, and the role of pharmacists. *Am J Health Syst Pharm.* 76(7),424-435.
2. Dunphy, C. (2021). Naloxone dispensing among the commercially insured population in the United States from 2015-2018. *Prev Med.* 153,100820.
3. Kirk, JK. (2021). Improving harm reduction with a naloxone intervention in primary care to prescribe and educate a support person. *J Opioid Manage.* 17(2),109-113.